Meinungen zu REPLIGEN CORPORATION - 500 Beiträge pro Seite
eröffnet am 29.07.05 22:26:16 von
neuester Beitrag 12.08.05 15:13:37 von
neuester Beitrag 12.08.05 15:13:37 von
Beiträge: 6
ID: 996.646
ID: 996.646
Aufrufe heute: 0
Gesamt: 1.451
Gesamt: 1.451
Aktive User: 0
ISIN: US7599161095 · WKN: 870980 · Symbol: RGEN
136,72
USD
-1,64 %
-2,28 USD
Letzter Kurs 05.10.24 NYSE
Neuigkeiten
Titel |
---|
24.09.24 · globenewswire |
23.08.24 · globenewswire |
19.08.24 · wO Chartvergleich |
07.08.24 · wO Chartvergleich |
30.07.24 · globenewswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
5,4500 | +699,12 | |
0,5997 | +73,32 | |
1,1600 | +41,60 | |
1,8500 | +36,03 | |
1,1000 | +34,46 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,6200 | -15,63 | |
1,2701 | -23,02 | |
2,5500 | -14,43 | |
0,9550 | -23,60 | |
15,600 | -13,33 |
Hallo !
Mich würde Eure Meinung zu Repligen interessieren.
Hier sind die letzten Zahlen:
July 27, 2005
Repligen Reports First Quarter 2006 Financial Results
Company Reports Net Profit of $2.2 M and Operating Profit of $881,000
WALTHAM, MA - July 27, 2005 - Repligen Corporation (NASDAQ: RGEN) today reported results for the first quarter of fiscal year 2006, ended June 30, 2005. Total revenue for the quarter was $4,239,000 compared to total revenue of $2,809,000 for the first quarter of fiscal year 2005, an increase of $1,430,000 or 51%. Total revenue for the first quarter consisted of $4,013,000 of Protein A and SecreFloTM sales and $226,000 of research revenue. Gross profit from product revenue for the first quarter of fiscal year 2006 was $3,040,000 (76%), compared to $1,676,000 (60%) for the same period in fiscal year 2005. This increase in profit margin was primarily due to increased customer demand, change in product mix and a decreased royalty obligation for SecreFloTM.
Operating expenses for the first quarter of fiscal year 2006 were $3,358,000 compared to $3,551,000 for the first quarter of fiscal year 2005. The net profit for the first quarter of fiscal year 2006 was $2,186,000 and basic and diluted earnings was $.07 per share. The net loss for the first quarter of fiscal year 2005 was $645,000 and basic and diluted net loss was $.02 per share. This quarter the Company recorded as other income $1,169,000 of a previously expensed but disputed royalty obligation that was reversed as a result of the SecreFloTM settlement in May 2005. Cash and investments as of June 30, 2005 were $24,894,000.
Mich würde Eure Meinung zu Repligen interessieren.
Hier sind die letzten Zahlen:
July 27, 2005
Repligen Reports First Quarter 2006 Financial Results
Company Reports Net Profit of $2.2 M and Operating Profit of $881,000
WALTHAM, MA - July 27, 2005 - Repligen Corporation (NASDAQ: RGEN) today reported results for the first quarter of fiscal year 2006, ended June 30, 2005. Total revenue for the quarter was $4,239,000 compared to total revenue of $2,809,000 for the first quarter of fiscal year 2005, an increase of $1,430,000 or 51%. Total revenue for the first quarter consisted of $4,013,000 of Protein A and SecreFloTM sales and $226,000 of research revenue. Gross profit from product revenue for the first quarter of fiscal year 2006 was $3,040,000 (76%), compared to $1,676,000 (60%) for the same period in fiscal year 2005. This increase in profit margin was primarily due to increased customer demand, change in product mix and a decreased royalty obligation for SecreFloTM.
Operating expenses for the first quarter of fiscal year 2006 were $3,358,000 compared to $3,551,000 for the first quarter of fiscal year 2005. The net profit for the first quarter of fiscal year 2006 was $2,186,000 and basic and diluted earnings was $.07 per share. The net loss for the first quarter of fiscal year 2005 was $645,000 and basic and diluted net loss was $.02 per share. This quarter the Company recorded as other income $1,169,000 of a previously expensed but disputed royalty obligation that was reversed as a result of the SecreFloTM settlement in May 2005. Cash and investments as of June 30, 2005 were $24,894,000.
die zahlen sehen ja erstmal ganz gut aus, daher auch der kurssprung
sicher ein unternehmen, das es auch in 10 jahren noch gibt
sicher ein unternehmen, das es auch in 10 jahren noch gibt
Machen sich heute wieder ganz gut:
Symbol: RGEN
Last Trade: 3.10 10:45AM ET
After Hours Change: N/A
Today`s Change: Up 0.30 (10.71%)
Bid: 3.06
Ask: 3.12
Gruß Cyberhai
Symbol: RGEN
Last Trade: 3.10 10:45AM ET
After Hours Change: N/A
Today`s Change: Up 0.30 (10.71%)
Bid: 3.06
Ask: 3.12
Gruß Cyberhai
sonst noch meinungen?
taugt das zeug als droge? ich meine, bei dem preis...
http://www.repligen.com/content.php?page_id=23
http://www.repligen.com/content.php?page_id=23
Machen wenigstens schon mal Umsätze. Ich denke das größte Potential hat noch folgendes Mittel:
Phase 2 Clinical Trial in Schizophrenia
The pathology of schizophrenia is marked by:
* "positive" symptoms such as hallucinations and disorganized speech,
* "negative" symptoms such as lack of initiative and social withdrawal,
* alterations in mood such as anxiety and depression,
* deficits in general cognition including the inability to learn and reason and
* deficits in social cognition including the processes we use to understand the world around us. Deficits in cognition are present at all stages of the disease, contribute to the rate of relapse and are predictive of long-term outcome.
We have completed a Phase 2 clinical trial of RG1068 in schizophrenia in patients who failed to respond to treatment with existing therapies. This trial was designed to extend the clinical results from investigators at the University of North Carolina in which 22 patients with refractory schizophrenia received a single dose of secretin. Several patients in the study were observed to have a marked, transient improvement in social interaction as measured by a physician`s rating scale (CGI). In our Phase 2 study, 24% of the RG1068 patients were rated by CGI as "much improved" after treatment, compared to 13% of placebo patients; however, this difference is not statistically significant due to the small number of patients in the study. In addition, several patients were evaluated within two hours of the first RG1068 treatment in a testing paradigm to assess the impact of secretin on a cognitive deficit characteristic of schizophrenics. The results suggest that further investigation of the impact of RG1068 on social cognition is warranted. We intend to conduct a follow-up study later this year to determine if this observation is reproducible and related to drug treatment.
Gruß Cyberhai
Phase 2 Clinical Trial in Schizophrenia
The pathology of schizophrenia is marked by:
* "positive" symptoms such as hallucinations and disorganized speech,
* "negative" symptoms such as lack of initiative and social withdrawal,
* alterations in mood such as anxiety and depression,
* deficits in general cognition including the inability to learn and reason and
* deficits in social cognition including the processes we use to understand the world around us. Deficits in cognition are present at all stages of the disease, contribute to the rate of relapse and are predictive of long-term outcome.
We have completed a Phase 2 clinical trial of RG1068 in schizophrenia in patients who failed to respond to treatment with existing therapies. This trial was designed to extend the clinical results from investigators at the University of North Carolina in which 22 patients with refractory schizophrenia received a single dose of secretin. Several patients in the study were observed to have a marked, transient improvement in social interaction as measured by a physician`s rating scale (CGI). In our Phase 2 study, 24% of the RG1068 patients were rated by CGI as "much improved" after treatment, compared to 13% of placebo patients; however, this difference is not statistically significant due to the small number of patients in the study. In addition, several patients were evaluated within two hours of the first RG1068 treatment in a testing paradigm to assess the impact of secretin on a cognitive deficit characteristic of schizophrenics. The results suggest that further investigation of the impact of RG1068 on social cognition is warranted. We intend to conduct a follow-up study later this year to determine if this observation is reproducible and related to drug treatment.
Gruß Cyberhai
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+1,85 | |
+3,72 | |
+2,06 | |
+0,63 | |
-0,04 | |
+0,07 | |
+0,31 | |
+1,63 | |
+0,89 | |
+0,10 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
76 | ||
42 | ||
30 | ||
28 | ||
25 | ||
22 | ||
20 | ||
19 | ||
18 | ||
16 |
24.09.24 · globenewswire · Repligen |
23.08.24 · globenewswire · Repligen |
19.08.24 · wO Chartvergleich · ALBIS Leasing |
07.08.24 · wO Chartvergleich · Casey's General Stores |
30.07.24 · globenewswire · Repligen |
29.07.24 · globenewswire · Repligen |
23.07.24 · wO Chartvergleich · The Descartes Systems Group |
16.07.24 · globenewswire · Repligen |
26.06.24 · wO Chartvergleich · Brown & Brown |
13.06.24 · globenewswire · Repligen |